JP2025508324A5 - - Google Patents
Info
- Publication number
- JP2025508324A5 JP2025508324A5 JP2024543863A JP2024543863A JP2025508324A5 JP 2025508324 A5 JP2025508324 A5 JP 2025508324A5 JP 2024543863 A JP2024543863 A JP 2024543863A JP 2024543863 A JP2024543863 A JP 2024543863A JP 2025508324 A5 JP2025508324 A5 JP 2025508324A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- nucleotides
- dsrna
- pkk
- complementary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022074535 | 2022-01-28 | ||
| CNPCT/CN2022/074535 | 2022-01-28 | ||
| PCT/CN2023/073501 WO2023143483A1 (en) | 2022-01-28 | 2023-01-28 | Compositions and methods for inhibiting expression of prekallikrein (pkk) protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508324A JP2025508324A (ja) | 2025-03-26 |
| JP2025508324A5 true JP2025508324A5 (https=) | 2026-02-02 |
Family
ID=87470605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543863A Pending JP2025508324A (ja) | 2022-01-28 | 2023-01-28 | プレカリクレイン（ｐｋｋ）タンパク質の発現を阻害するための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250145999A1 (https=) |
| EP (1) | EP4469570A1 (https=) |
| JP (1) | JP2025508324A (https=) |
| KR (1) | KR20240139057A (https=) |
| CN (1) | CN118510894A (https=) |
| AU (1) | AU2023210979A1 (https=) |
| CA (1) | CA3244243A1 (https=) |
| IL (1) | IL314396A (https=) |
| MX (1) | MX2024009257A (https=) |
| TW (1) | TW202346586A (https=) |
| WO (1) | WO2023143483A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12042509B2 (en) * | 2021-10-01 | 2024-07-23 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102365486B1 (ko) * | 2013-08-28 | 2022-02-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 프리칼리크레인 (pkk) 발현의 조절 |
| HUE052709T2 (hu) * | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| JP6695902B2 (ja) * | 2015-05-06 | 2020-05-20 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| CN109762904A (zh) * | 2019-03-05 | 2019-05-17 | 中国医学科学院北京协和医院 | 与胰腺神经内分泌肿瘤相关的分子标记物及其应用 |
| US20220315929A1 (en) * | 2019-05-24 | 2022-10-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
| WO2021126734A1 (en) * | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| BR112022015380A2 (pt) * | 2020-02-07 | 2022-09-27 | Intellia Therapeutics Inc | Composições e métodos para edição de gene de calicreína (klkb1) |
-
2023
- 2023-01-19 TW TW112102528A patent/TW202346586A/zh unknown
- 2023-01-28 MX MX2024009257A patent/MX2024009257A/es unknown
- 2023-01-28 EP EP23746361.7A patent/EP4469570A1/en active Pending
- 2023-01-28 AU AU2023210979A patent/AU2023210979A1/en active Pending
- 2023-01-28 CN CN202380015864.8A patent/CN118510894A/zh active Pending
- 2023-01-28 CA CA3244243A patent/CA3244243A1/en active Pending
- 2023-01-28 US US18/833,727 patent/US20250145999A1/en active Pending
- 2023-01-28 WO PCT/CN2023/073501 patent/WO2023143483A1/en not_active Ceased
- 2023-01-28 IL IL314396A patent/IL314396A/en unknown
- 2023-01-28 KR KR1020247025383A patent/KR20240139057A/ko active Pending
- 2023-01-28 JP JP2024543863A patent/JP2025508324A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6991966B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP2025134688A (ja) | α－１アンチトリプシン（ＡＡＴ）ＲＮＡｉ剤、ＡＡＴ ＲＮＡｉ剤を含む組成物、及び使用方法。 | |
| JP2023103244A5 (https=) | ||
| JP2025504863A5 (https=) | ||
| CN117701562A (zh) | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| JP7798881B2 (ja) | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 | |
| JP2021518125A5 (https=) | ||
| JP2018529732A5 (https=) | ||
| CN108064313A (zh) | 用于抑制因子xii的基因表达的组合物和方法 | |
| JP2024543496A5 (https=) | ||
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JP2018519797A5 (https=) | ||
| JP2024508896A5 (https=) | ||
| IL310929A (en) | Preparations and methods for inhibiting expression of angiopoietin-like protein 3 | |
| JP2024523000A5 (https=) | ||
| JP2025508324A5 (https=) | ||
| JP2020537653A (ja) | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 | |
| IL314396A (en) | Preparations and methods for inhibiting the expression of the parakallikrein protein (PKK) | |
| JP2025527670A (ja) | Ａｎｇｐｔｌ３関連疾患及び障害の治療方法 | |
| JP7846095B2 (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| JP2024534766A5 (https=) | ||
| RU2024121070A (ru) | Композиции и способы ингибирования экспрессии белка прекалликреина (ркк) | |
| JP2022546570A5 (https=) | ||
| RU2024124237A (ru) | Композиция и способ для подавления экспрессии белка lpa (apo(a)) | |
| KR20130121448A (ko) | ｍｉＲ－21 억제제를 유효성분으로 포함하는 허혈성 질환의 예방 또는 치료용 조성물 |